Possible contributions of reactive oxygen species and mitogen-activated protein kinase to renal injury in aldosterone/salt-induced hypertensive rats

DOI: 10.1161/01.hyp.0000118519.66430.22
Hypertension, 2004, 43, 841-8.

#	Paper	IF	Citations
265	Reactive oxygen species, vascular oxidative stress, and redox signaling in hypertension: what is the clinical significance?. *Hypertension*, **2004**, 44, 248-52	8.5	665
264	Mineralocorticoid receptor antagonists and hypertension: is there a rationale?. **2004**, 6, 279-87		11
263	Aldosterone and renal injury. **2004**, 124, 101-9		15
262	D-allose, an all-cis aldo-hexose, suppresses development of salt-induced hypertension in Dahl rats. *Journal of Hypertension*, **2005**, 23, 1887-94	1.9	39
261	Aldosterone and end-organ damage. **2005**, 14, 235-41		114
260	Bibliography Current World Literature. **2005**, 20, 324-368		
259	Endothelial progenitor cell senescence is accelerated in both experimental hypertensive rats and patients with essential hypertension. *Journal of Hypertension*, **2005**, 23, 1831-7	1.9	181
258	Aldosterone and end-organ damage. **2005**, 4, 381-387		1
257	Excess aldosterone under normal salt diet induces cardiac hypertrophy and infiltration via oxidative stress. *Hypertension Research*, **2005**, 28, 447-55	4.7	52
256	Cardioprotective mechanisms of spironolactone associated with the angiotensin-converting enzyme/epidermal growth factor receptor/extracellular signal-regulated kinases, NAD(P)H oxidase/lectin-like oxidized low-density lipoprotein receptor-1, and Rho-kinase pathways in aldosterone/salt-induced hypertensive rats. *Hypertension Research*, **2005**, 28, 925-36	4.7	66
255	Antihypertensive response to prolonged tempol in the spontaneously hypertensive rat. *Kidney International*, **2005**, 68, 179-87	9.9	54
254	The role of ERK5 in T-cell signalling. **2005**, 62, 515-20		14
253	The mineralocorticoid receptor and oxidative stress. **2005**, 10, 47-52		35
252	Androgen receptor gene knockout male mice exhibit impaired cardiac growth and exacerbation of angiotensin II-induced cardiac fibrosis. **2005**, 280, 29661-6		112
251	Involvement of aldosterone and mineralocorticoid receptors in rat mesangial cell proliferation and deformability. *Hypertension*, **2005**, 45, 710-6	8.5	115
250	Aldosterone stimulates reactive oxygen species production through activation of NADPH oxidase in rat mesangial cells. **2005**, 16, 2906-12		173
249	Role of NADPH Oxidase in Hypertension and Diabetic Nephropathy. **2005**, 1, 15-20		11

248	Aldosterone stimulates collagen gene expression and synthesis via activation of ERK1/2 in rat renal fibroblasts. *Hypertension*, **2005**, 46, 1039-45	8.5	125
247	Aldosterone stimulates vascular smooth muscle cell proliferation via big mitogen-activated protein kinase 1 activation. *Hypertension*, **2005**, 46, 1046-52	8.5	77
246	Aldosterone activates vascular p38MAP kinase and NADPH oxidase via c-Src. *Hypertension*, **2005**, 45, 773-9	8.5	204
245	Therapy of chronic renal insufficiency: from renal physiology to cardiovascular outcomes. *Therapy: Open Access in Clinical Medicine*, **2005**, 2, 425-437		
244	Eplerenone blocks nongenomic effects of aldosterone on the Na+/H+ exchanger, intracellular Ca2+ levels, and vasoconstriction in mesenteric resistance vessels. **2005**, 146, 973-80		112
243	Temporary angiotensin II blockade at the prediabetic stage attenuates the development of renal injury in type 2 diabetic rats. **2005**, 16, 703-11		107
242	c-Src-dependent nongenomic signaling responses to aldosterone are increased in vascular myocytes from spontaneously hypertensive rats. *Hypertension*, **2005**, 46, 1032-8	8.5	82
241	Reactive Oxygen Species, Nitric Oxide and Hypertensive Endothelial Dysfunction. **2005**, 1, 201-215		9
240	Enhanced aldosterone signaling in the early nephropathy of rats with metabolic syndrome: possible contribution of fat-derived factors. **2006**, 17, 3438-46		203
239	Augmentation of intrarenal angiotensin II levels in uninephrectomized aldosterone/salt-treated hypertensive rats; renoprotective effects of an ultrahigh dose of olmesartan. *Hypertension Research* , **2006**, 29, 169-78	4.7	32
238	Rapid non-genomic vasoconstrictor actions of aldosterone in the renal microcirculation. **2006**, 102, 170-4		5
237	Aldosterone and the kidney: rapid regulation of renal microcirculation. **2006**, 71, 281-5		12
236	Molecular mechanisms and therapeutic strategies of chronic renal injury: renoprotective effects of aldosterone blockade. **2006**, 100, 9-16		52
235	[Metabolic syndrome and aldosterone]. **2006**, 95, 1726-30		
234	Spironolactone with ACE inhibitor is effective in gross hematuria caused by nephroptosis. **2006**, 13, 990-2		4
233	Spironolactone ameliorates renal injury and connective tissue growth factor expression in type II diabetic rats. *Kidney International*, **2006**, 70, 111-20	9.9	71
232	Interferon-gamma enhances superoxide production in human mesangial cells via the JAK-STAT pathway. *Kidney International*, **2006**, 70, 788-93	9.9	22
231	The effect of aldosterone blockade in patients with Alport syndrome. **2006**, 21, 1824-9		33

230	Aldosterone blockade attenuates urinary monocyte chemoattractant protein-1 and oxidative stress in patients with type 2 diabetes complicated by diabetic nephropathy. **2006**, 91, 2214-7		89
229	Effects of adrenomedullin on cardiac oxidative stress and collagen accumulation in aldosterone-dependent malignant hypertensive rats. **2006**, 318, 1323-9		26
228	Addition of the antioxidant probucol to angiotensin II type I receptor antagonist arrests progressive mesangioproliferative glomerulonephritis in the rat. **2006**, 17, 783-94		38
227	Aldosterone antagonism in chronic kidney disease. **2006**, 1, 668-77		48
226	Involvements of Rho-kinase and TGF-beta pathways in aldosterone-induced renal injury. **2006**, 17, 2193-201		99
225	Sustained renal interstitial macrophage infiltration following chronic angiotensin II infusions. *American Journal of Physiology - Renal Physiology*, **2007**, 292, F330-9	4.3	121
224	Aldosterone promotes proximal tubular cell apoptosis: role of oxidative stress. *American Journal of Physiology - Renal Physiology*, **2007**, 293, F1065-71	4.3	58
223	Antagonistic effects of bone morphogenetic protein-4 and -7 on renal mesangial cell proliferation induced by aldosterone through MAPK activation. *American Journal of Physiology - Renal Physiology*, **2007**, 292, F1513-25	4.3	45
222	Mechanisms of disease: The role of aldosterone in kidney damage and clinical benefits of its blockade. **2007**, 3, 42-9		40
221	Aldosterone-induced EGFR expression: interaction between the human mineralocorticoid receptor and the human EGFR promoter. **2007**, 292, E1790-800		65
220	Depolarization of the macula densa induces superoxide production via NAD(P)H oxidase. *American Journal of Physiology - Renal Physiology*, **2007**, 292, F1867-72	4.3	39
219	Sodium in Health and Disease. **2007**,		3
218	Dual blockade of aldosterone and angiotensin II additively suppresses TGF-beta and NADPH oxidase in the hypertensive kidney. **2007**, 22, 1314-22		71
217	Angiotensin II receptor type 1-mediated vascular oxidative stress and proinflammatory gene expression in aldosterone-induced hypertension: the possible role of local renin-angiotensin system. **2007**, 148, 1688-96		90
216	Podocyte as the target for aldosterone: roles of oxidative stress and Sgk1. *Hypertension*, **2007**, 49, 355-64	8.5	270
215	Reactive oxygen species-dependent hypertension in dopamine D2 receptor-deficient mice. *Hypertension*, **2007**, 49, 672-8	8.5	58
214	[Molecular mechanism of cardiovascular damage induced by aldosterone]. **2007**, 127, 1339-46		2
213	[Role of aldosterone in oxidative stress and renal injury]. **2007**, 127, 1331-7		4

212	Aldosterone as a cardiovascular risk hormone. **2007**, 54, 359-70		32
211	Aldosterone and end-organ damage. *Clinical Science*, **2007**, 113, 267-78	6.5	166
210	Female protection in progressive renal disease is associated with estradiol attenuation of superoxide production. **2007**, 4, 56-71		54
209	Nox enzymes, ROS, and chronic disease: an example of antagonistic pleiotropy. **2007**, 43, 332-47		499
208	Aldosterone and glomerular podocyte injury. **2008**, 12, 233-242		57
207	Aldosterone induces collagen synthesis via activation of extracellular signal-regulated kinase 1 and 2 in renal proximal tubules. *Nephrology*, **2008**, 13, 694-701	2.2	10
206	Time-course reduction of renal function in rats on high sodium intake: acute reversal by potassium canrenoate. *Clinical and Experimental Pharmacology and Physiology*, **2008**, 35, 412-5	3	1
205	Aldosterone induces myofibroblastic transdifferentiation and collagen gene expression through the Rho-kinase dependent signaling pathway in rat mesangial cells. **2008**, 314, 3654-62		34
204	Spironolactone exhibits direct renoprotective effects and inhibits renal renin-angiotensin-aldosterone system in diabetic rats. **2008**, 589, 264-71		65
203	Synergy of aldosterone and high salt induces vascular smooth muscle hypertrophy through up-regulation of NOX1. **2008**, 111, 29-36		24
202	Mechanisms underlying sex differences in progressive renal disease. **2008**, 5, 10-23		35
201	Aldosterone and vascular inflammation. *Hypertension*, **2008**, 51, 161-7	8.5	176
200	Chemistry and antihypertensive effects of tempol and other nitroxides. **2008**, 60, 418-69		285
199	Spironolactone suppresses peritubular capillary loss and prevents deoxycorticosterone acetate/salt-induced tubulointerstitial fibrosis. *Hypertension*, **2008**, 51, 749-54	8.5	22
198	The aggravating mechanisms of aldosterone on kidney fibrosis. **2008**, 19, 1459-62		86
197	Aldosterone induces mesangial cell apoptosis both in vivo and in vitro. *American Journal of Physiology - Renal Physiology*, **2008**, 295, F73-81	4.3	36
196	Intermedin ameliorates vascular and renal injury by inhibition of oxidative stress. *American Journal of Physiology - Renal Physiology*, **2008**, 295, F1735-43	4.3	37
195	Does increased oxidative stress cause hypertension?. **2008**, 31 Suppl 2, S185-9		112

194	Aldosterone-stimulated SGK1 activity mediates profibrotic signaling in the mesangium. **2008**, 19, 298-309		58
193	History of hypertension and eplerenone in patients with acute myocardial infarction complicated by heart failure. *Hypertension*, **2008**, 52, 271-8	8.5	21
192	Possible underlying mechanisms responsible for aldosterone and mineralocorticoid receptor-dependent renal injury. **2008**, 108, 399-405		47
191	Novel Therapeutic Targets for the Treatment of Tubulointerstitial Fibrosis. **2008**, 3, 97-111		4
190	Strict angiotensin blockade prevents the augmentation of intrarenal angiotensin II and podocyte abnormalities in type 2 diabetic rats with microalbuminuria. *Journal of Hypertension*, **2008**, 26, 1849-59	1.9	37
189	Expression of NAD(P)H oxidase subunits and their contribution to cardiovascular damage in aldosterone/salt-induced hypertensive rat. **2008**, 23, 1039-45		26
188	Aldosterone and progression of kidney disease. **2009**, 3, 133-43		12
187	Peritoneal mesothelial cells as a target of local aldosterone action: upregulation of connective tissue growth factor expression via serum- and glucocorticoid-inducible protein kinase 1. **2009**, 32, 151-60		8
186	Differential effects of 17beta-estradiol and of synthetic progestins on aldosterone-salt-induced kidney disease. **2009**, 37, 969-82		16
185	Aldosterone in clinical nephrology--old hormone, new questions. **2009**, 24, 2316-21		7
184	Mineralocorticoid receptor activation in obesity hypertension. *Hypertension Research*, **2009**, 32, 649-57	4.7	37
183	Low-density lipoprotein apheresis for haemodialysis patients with peripheral arterial disease reduces reactive oxygen species production via suppression of NADPH oxidase gene expression in leucocytes. **2009**, 24, 3818-25		14
182	Actions of aldosterone in the cardiovascular system: the good, the bad, and the ugly?. **2009**, 458, 231-46		59
181	Role of aldosterone in the progression of chronic kidney disease and potential use of aldosterone blockade in children. **2009**, 24, 2301-7		6
180	Epidemiologic and pathophysiologic links between obesity and hypertension. **2009**, 3, 264-271		2
179	Endothelial progenitor cells and their potential clinical implication in cardiovascular disorders. **2009** , 32, 370-82		13
178	Inhibition of hepatic stellate cells proliferation by mesenchymal stem cells and the possible mechanisms. **2009**, 39, 1219-28		35
177	Inhibitory effects of a dihydropyridine calcium channel blocker on renal injury in aldosterone-infused rats. *Journal of Hypertension*, **2009**, 27, 1855-62	1.9	16

176	Drug discovery for overcoming chronic kidney disease (CKD): pharmacological effects of mineralocorticoid-receptor blockers. **2009**, 109, 1-6		27
175	[Kidney diseases and mineralocorticoid receptor]. **2009**, 98, 2894-902		
174	Molecular mechanisms of hypertension: role of Nox family NADPH oxidases. **2009**, 18, 122-7		120
173	Involvement of mineralocorticoid receptor in high glucose-induced big mitogen-activated protein kinase 1 activation and mesangial cell proliferation. *Journal of Hypertension*, **2010**, 28, 536-42	1.9	9
172	Aldosterone and inflammation. **2010**, 17, 199-204		97
171	Effects of tempol and redox-cycling nitroxides in models of oxidative stress. **2010**, 126, 119-45		319
170	Protein kinase C-delta is involved in induction of NOX1 gene expression by aldosterone in rat vascular smooth muscle cells. **2010**, 75, 304-9		8
169	Effects of mineralocorticoid and angiotensin II receptor blockers on proteinuria and glomerular podocyte protein expression in a model of minimal change nephrotic syndrome. *Nephrology*, **2010**, 15, 321-6	2.2	17
168	Superoxide anion and hydrogen peroxide-induced signaling and damage in angiotensin II and aldosterone action. **2010**, 391, 1265-79		29
167	Mineralocorticoid receptor blockade enhances the antiproteinuric effect of an angiotensin II blocker through inhibiting podocyte injury in type 2 diabetic rats. **2010**, 332, 1072-80		40
166	Oxidative stress and endothelial dysfunction in aortas of aged spontaneously hypertensive rats by NOX1/2 is reversed by NADPH oxidase inhibition. *Hypertension*, **2010**, 56, 490-7	8.5	132
165	Total antioxidant status and oxidative DNA damage in a South Indian population of essential hypertensives. **2010**, 24, 475-82		16
164	High-salt intake enhances superoxide activity in eNOS knockout mice leading to the development of salt sensitivity. *American Journal of Physiology - Renal Physiology*, **2010**, 299, F656-63	4.3	36
163	Mineralocorticoid receptor activation contributes to salt-induced hypertension and renal injury in prepubertal Dahl salt-sensitive rats. **2010**, 25, 2879-89		21
162	Aldosterone: effects on the kidney and cardiovascular system. **2010**, 6, 261-73		233
161	Protein kinase D stabilizes aldosterone-induced ERK1/2 MAP kinase activation in M1 renal cortical collecting duct cells to promote cell proliferation. **2010**, 118, 18-28		28
160	Role of Rho kinase and oxidative stress in cardiac fibrosis induced by aldosterone and salt in angiotensin type 1a receptor knockout mice. **2010**, 160, 133-9		24
159	Vasculoprotective effect of cilostazol in aldosterone-induced hypertensive rats. *Hypertension Research*, **2010**, 33, 229-35	4.7	11

158	The regulation of cell growth and survival by aldosterone. **2011**, 16, 440-57		18
157	Endocrinological aspects of proteinuria and podocytopathy in diabetes: role of the aldosterone/mineralocorticoid receptor system. **2011**, 7, 8-16		7
156	Structural, functional, and molecular alterations produced by aldosterone plus salt in rat heart: association with enhanced serum and glucocorticoid-regulated kinase-1 expression. **2011**, 57, 114-21		17
155	Effects of mineralocorticoid receptor blockade on glucocorticoid-induced renal injury in adrenalectomized rats. *Journal of Hypertension*, **2011**, 29, 290-8	1.9	40
154	Matrix metalloproteinase 2 induces epithelial-mesenchymal transition in proximal tubules from the luminal side and progresses fibrosis in mineralocorticoid/salt-induced hypertensive rats. *Journal of Hypertension*, **2011**, 29, 2440-53	1.9	12
153	Aldosterone as a modulator of immunity: implications in the organ damage. *Journal of Hypertension* , **2011**, 29, 1684-92	1.9	48
152	Pre-clinical data on the role of mineralocorticoid receptor antagonists in reversing vascular inflammation. **2011**, 13, B15-B20		1
151	Activation of Src-ATF1 pathway is involved in upregulation of Nox1, a catalytic subunit of NADPH oxidase, by aldosterone. **2011**, 58, 491-9		13
150	The Western-style diet: a major risk factor for impaired kidney function and chronic kidney disease. *American Journal of Physiology - Renal Physiology*, **2011**, 301, F919-31	4.3	143
149	Pathophysiological roles of aldosterone and mineralocorticoid receptor in the kidney. **2011**, 115, 1-7		38
148	Association of plasma aldosterone with cardiovascular mortality in patients with low estimated GFR: the Ludwigshafen Risk and Cardiovascular Health (LURIC) Study. **2011**, 57, 403-14		37
147	The role of aldosterone in the metabolic syndrome. **2011**, 13, 163-72		67
146	Oxidative damages in tubular epithelial cells in IgA nephropathy: role of crosstalk between angiotensin II and aldosterone. **2011**, 9, 169		22
145	Disparate effects of eplerenone, amlodipine and telmisartan on podocyte injury in aldosterone-infused rats. **2011**, 26, 789-99		18
144	Mineralocorticoid receptor antagonism: therapeutic potential in acute heart failure syndromes. **2011**, 32, 2626-33		32
143	Aldosterone/Mineralocorticoid receptor stimulation induces cellular senescence in the kidney. **2011**, 152, 680-8		39
142	Chronic angiotensin receptor blockade suppresses intracardiac angiotensin II in angiotensin II-infused rats. **2011**, 236, 1449-53		3
141	Eplerenone suppresses aldosterone/ salt-induced expression of NOX-4. **2011**, 12, 195-201		26

140	Induction of oxidative stress in kidney. **2012**, 2012, 465897		195
139	From form to function: the role of Nox4 in the cardiovascular system. **2012**, 3, 412		108
138	Eplerenone inhibits aldosterone-induced renal expression of cyclooxygenase. **2012**, 13, 353-9		3
137	Role of mineralocorticoid receptor/Rho/Rho-kinase pathway in obesity-related renal injury. **2012**, 36, 1062-71		26
136	Enhanced expression of bone morphogenetic protein system in aldosterone-treated mouse kidneys. *Hypertension Research*, **2012**, 35, 312-7	4.7	6
135	Spironolactone improves nephropathy by enhancing glucose-6-phosphate dehydrogenase activity and reducing oxidative stress in diabetic hypertensive rat. **2012**, 13, 56-66		28
134	Natriuretic peptide receptor guanylyl cyclase-A protects podocytes from aldosterone-induced glomerular injury. **2012**, 23, 1198-209		50
133	Renal sympathetic denervation suppresses de novo podocyte injury and albuminuria in rats with aortic regurgitation. **2012**, 125, 1402-13		91
132	Failure to downregulate the epithelial sodium channel causes salt sensitivity in Hsd11b2 heterozygote mice. *Hypertension*, **2012**, 60, 684-90	8.5	20
131	Aldosterone does not contribute to renal p21 expression during the development of angiotensin II-induced hypertension in mice. *American Journal of Hypertension*, **2012**, 25, 354-8	2.3	3
130	Antihypertensive and cardiorenal protective effects of SM-368229, a novel mineralocorticoid receptor antagonist, in aldosterone/salt-treated rats. **2012**, 89, 44-52		19
129	Long-term mineralocorticoid receptor blockade ameliorates progression of experimental diabetic renal disease. **2012**, 27, 906-12		20
128	Mineralocorticoid receptor--Rac1 activation and oxidative stress play major roles in salt-induced hypertension and kidney injury in prepubertal rats. *Journal of Hypertension*, **2012**, 30, 1977-85	1.9	28
127	[Mechanisms responsible for the renoprotective effects of renin-angiotensin inhibitors]. **2012**, 132, 455-9		3
126	N-type calcium channel inhibition with cilnidipine elicits glomerular podocyte protection independent of sympathetic nerve inhibition. **2012**, 119, 359-67		10
125	Add-on aliskiren elicits stronger renoprotection than high-dose valsartan in type 2 diabetic KKAy mice that do not respond to low-dose valsartan. **2012**, 119, 131-8		11
124	Aldosterone induces p21-regulated apoptosis via increased synthesis and secretion of tumour necrosis factor-α in human proximal tubular cells. *Clinical and Experimental Pharmacology and Physiology*, **2012**, 39, 858-863	3	11
123	PVN adenovirus-siRNA injections silencing either NOX2 or NOX4 attenuate aldosterone/NaCl-induced hypertension in mice. **2012**, 302, H733-41		36

122	Lipid peroxidation the levels of antioxidant enzymes in hypertension. **2012**, 2, 12-18		5
121	Chronic inhibition of nuclear factor kappa B attenuates aldosterone/salt-induced renal injury. **2012**, 90, 600-6		23
120	The new role of LOX-1 in hypertension induced neuronal apoptosis. **2012**, 425, 735-40		21
119	Biochemistry, physiology, and pathophysiology of NADPH oxidases in the cardiovascular system. **2012**, 110, 1364-90		574
118	Pendrin protein abundance in the kidney is regulated by nitric oxide and cAMP. *American Journal of Physiology - Renal Physiology*, **2012**, 303, F812-20	4.3	8
117	The antioxidant tempol ameliorates arterial medial calcification in uremic rats: important role of oxidative stress in the pathogenesis of vascular calcification in chronic kidney disease. **2012**, 27, 474-85		81
116	Prevention of salt-induced renal injury by activation of NAD(P)H:quinone oxidoreductase 1, associated with NADPH oxidase. **2012**, 52, 880-8		37
115	Aldosterone, oxidative stress, and NF-B activation in hypertension-related cardiovascular and renal diseases. **2012**, 53, 314-27		42
114	Cisplatin-induced acute renal failure in mice is mediated by chymase-activated angiotensin-aldosterone system and interleukin-18. **2012**, 685, 149-55		21
113	Role of the renin-angiotensin-aldosterone system in the enhancement of salt sensitivity caused by prenatal protein restriction in stroke-prone spontaneously hypertensive rats. **2012**, 23, 892-9		10
112	Mineralocorticoid receptors in vascular function and disease. **2012**, 350, 256-65		120
111	Tissue-specific modulation of mineralocorticoid receptor function by 11hydroxysteroid dehydrogenases: an overview. **2012**, 350, 168-86		117
110	Mechanisms of mineralocorticoid salt-induced hypertension and cardiac fibrosis. **2012**, 350, 248-55		51
109	Aldosterone stimulates nuclear factor-kappa B activity and transcription of intercellular adhesion molecule-1 and connective tissue growth factor in rat mesangial cells via serum- and glucocorticoid-inducible protein kinase-1. **2012**, 16, 81-8		45
108	Aldosterone stimulates fibronectin synthesis in renal fibroblasts through mineralocorticoid receptor-dependent and independent mechanisms. **2013**, 531, 23-30		29
107	Antioxidant N-acetylcysteine protects pancreatic cells against aldosterone-induced oxidative stress and apoptosis in female db/db mice and insulin-producing MIN6 cells. **2013**, 154, 4068-77		29
106	Blood pressure has only minor influence on aldosterone-induced oxidative stress and DNA damage in vivo. **2013**, 54, 17-25		29
105	Opportunity nox: the future of NADPH oxidases as therapeutic targets in cardiovascular disease. **2013**, 31, 125-37		52

104	Aldosterone aggravates glucose intolerance induced by high fructose. **2013**, 720, 63-8		16
103	Effects of imperatorin, the active component from Radix Angelicae (Baizhi), on the blood pressure and oxidative stress in 2K,1C hypertensive rats. **2013**, 20, 1048-54		44
102	Reactive oxygen species, Nox and angiotensin II in angiogenesis: implications for retinopathy. *Clinical Science*, **2013**, 124, 597-615	6.5	106
101	Direct contribution of vascular mineralocorticoid receptors to blood pressure regulation. *Clinical and Experimental Pharmacology and Physiology*, **2013**, 40, 902-9	3	16
100	Mineralocorticoid receptor blockade reduced oxidative stress in renal transplant recipients: a double-blind, randomized pilot study. **2013**, 37, 481-90		27
99	Interaction between nitric oxide and superoxide in the macula densa in aldosterone-induced alterations of tubuloglomerular feedback. *American Journal of Physiology - Renal Physiology*, **2013**, 304, F326-32	4.3	14
98	Nitric oxide reduces Cl? absorption in the mouse cortical collecting duct through an ENaC-dependent mechanism. *American Journal of Physiology - Renal Physiology*, **2013**, 304, F1390-7	4.3	18
97	Rho kinase pathway is likely responsible for the profibrotic actions of aldosterone in renal epithelial cells via inducing epithelial-mesenchymal transition and extracellular matrix excretion. **2013**, 37, 725-30		14
96	Reduction of aldosterone production improves renal oxidative stress and fibrosis in diabetic rats. **2013**, 61, 17-22		19
95	Beneficial effects of proanthocyanidins in the cardiac alterations induced by aldosterone in rat heart through mineralocorticoid receptor blockade. **2014**, 9, e111104		10
94	Relevance of SGK1 in structural, functional and molecular alterations produced by aldosterone in heart. **2014**, 18, 53-61		5
93	Ginsenoside Rg1 protects mouse podocytes from aldosterone-induced injury in vitro. **2014**, 35, 513-22		21
92	Cerebral oxidative stress induces spatial working memory dysfunction in uremic mice: neuroprotective effect of tempol. **2014**, 29, 529-38		53
91	Contributions of endoplasmic reticulum stress and reactive oxygen species to renal injury in aldosterone/salt-induced rats. **2014**, 126, 25-32		8
90	Telmisartan reduces progressive oxidative stress and phosphorylated □synuclein accumulation in stroke-resistant spontaneously hypertensive rats after transient middle cerebral artery occlusion. **2014**, 23, 1554-63		15
89	Spironolactone decreases DOCA-salt-induced organ damage by blocking the activation of T helper 17 and the downregulation of regulatory T lymphocytes. *Hypertension*, **2014**, 63, 797-803	8.5	126
88	Oxidative stress and organ damages. **2014**, 16, 452		44
87	Metabolic acidosis and the progression of chronic kidney disease. **2014**, 15, 55		48

86	Aldosterone blockade in chronic kidney disease. **2014**, 34, 307-22		18
85	Oxidative stress in hypertension: role of the kidney. *Antioxidants and Redox Signaling*, **2014**, 20, 74-101	8.4	127
84	Analysis of differentially expressed genes in cold-exposed mice to investigate the potential causes of cold-induced hypertension. **2014**, 8, 110-114		6
83	Salt intake and mental distress among rural community-dwelling Japanese men. **2015**, 34, 26		5
82	Angiotensin and mineralocorticoid receptor antagonism attenuates cardiac oxidative stress in angiotensin II-infused rats. *Clinical and Experimental Pharmacology and Physiology*, **2015**, 42, 1178-88	3	13
81	Modulation of Immunity and Inflammation by the Mineralocorticoid Receptor and Aldosterone. **2015**, 2015, 652738		28
80	Iron restriction inhibits renal injury in aldosterone/salt-induced hypertensive mice. *Hypertension Research*, **2015**, 38, 317-22	4.7	11
79	Finerenone : third-generation mineralocorticoid receptor antagonist for the treatment of heart failure and diabetic kidney disease. **2015**, 24, 1123-35		40
78	Oxidative stress, oxidative balance score, and hypertension among a racially diverse population. **2015**, 9, 592-9		16
77	Human liver-type fatty acid-binding protein protects against tubulointerstitial injury in aldosterone-induced renal injury. *American Journal of Physiology - Renal Physiology*, **2015**, 308, F114-21	4.3	10
76	Safety and Antihypertensive Effect of Selara (Eplerenone): Results from a Postmarketing Surveillance in Japan. **2016**, 2016, 5091951		8
75	Pitavastatin Exhibits Protective Effects on Podocytes Accompanied by BMP-7 Up-Regulation and Rho Suppression. **2016**, 97, 265-76		11
74	A serine protease inhibitor attenuates aldosterone-induced kidney injuries via the suppression of plasmin activity. **2016**, 132, 145-153		4
73	Current Understanding of the Pathogenesis of Progressive Chronic Kidney Disease in Cats. **2016**, 46, 1015-48		25
72	CS-3150, a Novel Nonsteroidal Mineralocorticoid Receptor Antagonist, Shows Preventive and Therapeutic Effects On Renal Injury in Deoxycorticosterone Acetate/Salt-Induced Hypertensive Rats. **2016**, 358, 548-57		39
71	Epidermal growth factor receptor signaling mediates aldosterone-induced profibrotic responses in kidney. **2016**, 346, 99-110		20
70	Antihypertensive effects of fargesin in vitro and in vivo via attenuating oxidative stress and promoting nitric oxide release. **2016**, 94, 900-6		9
69	Selective Synthesis of Partially Protected d-Talopyranosides and d-Gulopyranosides via Catalytic Asymmetric Dihydroxylation: Multiplier Effects of Substrate Control and Catalyst Control. **2016**, 18, 6058-6061		1

68	NADPH oxidases and vascular remodeling in cardiovascular diseases. **2016**, 114, 110-120		88
67	Age-related changes in hypertensive brain damage in the hippocampi of spontaneously hypertensive rats. *Molecular Medicine Reports*, **2016**, 13, 2552-60	2.9	13
66	Effects of p53 on aldosterone-induced mesangial cell apoptosis in vivo and in vitro. *Molecular Medicine Reports*, **2016**, 13, 5102-8	2.9	6
65	Alteration of amiloride-sensitive salt taste nerve responses in aldosterone/NaCl-induced hypertensive rats. *Neuroscience Research*, **2016**, 108, 60-6	2.9	14
64	The Role of Aldosterone in Obesity-Related Hypertension. *American Journal of Hypertension*, **2016**, 29, 415-23	2.3	78
63	Aldosterone activates the oncogenic signals ERK1/2 and STAT3 via redox-regulated mechanisms. *Molecular Carcinogenesis*, **2017**, 56, 1868-1883	5	6
62	Natriuretic peptide receptor guanylyl cyclase-A pathway counteracts glomerular injury evoked by aldosterone through p38 mitogen-activated protein kinase inhibition. *Scientific Reports*, **2017**, 7, 46624	4.9	12
61	Alterations in the long non-coding RNA transcriptome in mesangial cells treated with aldosterone in vitro. *Molecular Medicine Reports*, **2017**, 16, 6004-6012	2.9	2
60	Microvesicles derived from human Wharton's Jelly mesenchymal stem cells ameliorate ischemia-reperfusion-induced renal fibrosis by releasing from G2/M cell cycle arrest. *Biochemical Journal*, **2017**, 474, 4207-4218	3.8	20
59	Nitroxides as Antioxidants and Anticancer Drugs. *International Journal of Molecular Sciences*, **2017**, 18,	6.3	53
58	Prevalence of Cardiovascular Disease and Its Risk Factors in Primary Aldosteronism: A Multicenter Study in Japan. *Hypertension*, **2018**, 71, 530-537	8.5	81
57	Nitrolipids in kidney physiology and disease. *Nitric Oxide - Biology and Chemistry*, **2018**, 78, 121-121	5	7
56	Effects of Diesel Exhaust on Cardiovascular Function and Oxidative Stress. *Antioxidants and Redox Signaling*, **2018**, 28, 819-836	8.4	33
55	In vitro and in vivo study of the expression of the Syk/Ras/c-Fos pathway in chronic glomerulonephritis. *Molecular Medicine Reports*, **2018**, 18, 3683-3690	2.9	4
54	Effects of drought stress on photosynthesis and photosynthetic electron transport chain in young apple tree leaves. *Biology Open*, **2018**, 7,	2.2	78
53	Serum-soluble (pro)renin receptor concentration as a biomarker for organ damage in primary aldosteronism. *Hypertension Research*, **2019**, 42, 1951-1960	4.7	4
52	Role of Aldosterone in Renal Fibrosis. *Advances in Experimental Medicine and Biology*, **2019**, 1165, 325-346	3.6	19
51	Spironolactone reduces oxidative stress in living donor kidney transplantation: a randomized controlled trial. *American Journal of Physiology - Renal Physiology*, **2019**, 317, F519-F528	4.3	5

50	Role of Aldosterone and Mineralocorticoid Receptor in Cardiovascular Aging. *Frontiers in Endocrinology*, **2019**, 10, 584	5.7	26
49	Diverse associations between oxidative stress and thromboxane A in hypertensive glomerular injury. *Hypertension Research*, **2019**, 42, 450-458	4.7	6
48	Effect of a novel nonsteroidal selective mineralocorticoid receptor antagonist, esaxerenone (CS-3150), on blood pressure and renal injury in high salt-treated type 2 diabetic mice. *Hypertension Research*, **2019**, 42, 892-902	4.7	17
47	Mineralocorticoid receptor antagonists and kidney diseases: pathophysiological basis. *Kidney International*, **2019**, 96, 302-319	9.9	81
46	The effect of fludrocortisone on the uterine receptivity partially mediated by ERK1/2-mTOR pathway. *Journal of Cellular Physiology*, **2019**, 234, 20098-20110	7	6
45	Potential Benefit of Mineralocorticoid Receptor Antagonists in Kidney Diseases. **2019**,		
44	Nitroxide Functionalized Antibiotics Are Promising Eradication Agents against Staphylococcus aureus Biofilms. *Antimicrobial Agents and Chemotherapy*, **2019**, 64,	5.9	7
43	Effects of the novel nonsteroidal mineralocorticoid receptor blocker, esaxerenone (CS-3150), on blood pressure and urinary angiotensinogen in low-renin Dahl salt-sensitive hypertensive rats. *Hypertension Research*, **2019**, 42, 769-778	4.7	16
42	The Race to Bash NASH: Emerging Targets and Drug Development in a Complex Liver Disease. *Journal of Medicinal Chemistry*, **2020**, 63, 5031-5073	8.3	35
41	Hormones and oxidative stress: an overview. *Free Radical Research*, **2020**, 54, 1-26	4	48
40	Aldosterone and the mineralocorticoid receptor in renal injury: A potential therapeutic target in feline chronic kidney disease. *Journal of Veterinary Pharmacology and Therapeutics*, **2020**, 43, 243-267	1.4	7
39	Selective Synthesis of Some Aminosugars via Catalytic Aminohydroxylation of Protected 2,3-Unsaturated d-Gluco- and d-Galacto-2-hexenopyranosides. *Journal of Organic Chemistry*, **2020**, 85, 9179-9189	4.2	2
38	Role of mineralocorticoid receptor antagonists in kidney diseases. *Drug Development Research*, **2021**, 82, 341-363	5.1	13
37	microRNA-363-3p reduces endothelial cell inflammatory responses in coronary heart disease via inactivation of the -dependent p38 MAPK axis. *Aging*, **2021**, 13, 11061-11082	5.6	5
36	Sodium-glucose cotransporter-2 inhibitors and non-steroidal mineralocorticoid receptor antagonists: Ushering in a new era of nephroprotection beyond renin-angiotensin system blockade. *Nephrology*, **2021**, 26, 858-871	2.2	2
35	Sex-related response in mice after sub-acute intraperitoneal exposure to silver nanoparticles.. *NanoImpact*, **2021**, 23, 100340	5.6	3
34	Glomerular Mesangial Cell pH Homeostasis Mediates Mineralocorticoid Receptor-Induced Cell Proliferation. *Biomedicines*, **2021**, 9,	4.8	0
33	Renin-Angiotensin System in the Kidney and Oxidative Stress: Local Renin-Angiotensin-Aldosterone System and NADPH Oxidase-Dependent Oxidative Stress in the Kidney. **2011**, 71-91		2

32	Role of bardoxolone methyl, a nuclear factor erythroid 2-related factor 2 activator, in aldosterone- and salt-induced renal injury. *Hypertension Research*, **2018**, 41, 8-17	4.7	16
31	The growth factor midkine regulates the renin-angiotensin system in mice. *Journal of Clinical Investigation*, **2009**, 119, 1616-25	15.9	64
30	Rac1 GTPase in rodent kidneys is essential for salt-sensitive hypertension via a mineralocorticoid receptor-dependent pathway. *Journal of Clinical Investigation*, **2011**, 121, 3233-43	15.9	155
29	Elevation of Oxidative Stress and Decline in Endogenous Antioxidant Defense in Elderly Individuals with Hypertension. *Journal of Clinical and Diagnostic Research JCDR*, **2017**, 11, BC09-BC12	0	7
28	????????(????2004????). *Journal of JCS Cardiologists*, **2005**, 13, 109-114	0.1	
27	Drug-induced Alterations of Sodium Balance: The Example of Nonsteroidal Anti-in□mmatory Agents. **2007**, 399-414		
26	3.??????????????????. *Japanese Journal of Clinical Pharmacology and Therapeutics*, **2009**, 40, 47S-48S	0	
25	5. RAS??????????????????CKD??. *Japanese Journal of Clinical Pharmacology and Therapeutics*, **2011**, 42, 193-194		
24	Unpuzzling the Comorbid Type 2 Diabetes and Hypertension-Related Cognitive Dysfunction and Stroke. *Springer Series in Translational Stroke Research*, **2017**, 711-731	0.1	1
23	Comparison of the shortened and standard saline infusion tests for primary aldosteronism diagnostics. *Hypertension Research*, **2020**, 43, 1113-1121	4.7	0
22	[PLASMA RENIN ACTIVITY AND ALDOSTERONE IN RENAL TRANSPLANT PATIENTS]. *Japanese Journal of Urology*, **2020**, 111, 74-81		0
21	Therapy of chronic renal insufficiency: from renal physiology to cardiovascular outcomes. *Therapy: Open Access in Clinical Medicine*, **2005**, 2, 425-437		
20	Aldosterone induces p21-regulated apoptosis via increased synthesis and secretion of tumour necrosis factor-□n human proximal tubular cells. *Clinical and Experimental Pharmacology and Physiology*, **2012**, 39, 858-63	3	7
19	Spironolactone inhibits NADPH oxidase-induced oxidative stress and enhances eNOS in human endothelial cells. *Iranian Journal of Pharmaceutical Research*, **2011**, 10, 329-37	1.1	18
18	Higher aldosterone is associated with increased renal impairment risk in patients with hypertension and abnormal glucose metabolism: a longitudinal study. *Journal of Hypertension*, **2021**,	1.9	0
17	Obesity and Cardiometabolic Risk Factors: From Childhood to Adulthood. *Nutrients*, **2021**, 13,	6.7	17
16	Improving the residual risk of renal and cardiovascular outcomes in diabetic kidney disease: A review of pathophysiology, mechanisms, and evidence from recent trials. *Diabetes, Obesity and Metabolism*, **2021**,	6.7	6
15	Cerebro-Cardiovascular Risk, Target Organ Damage, and Treatment Outcomes in Primary Aldosteronism.. *Frontiers in Cardiovascular Medicine*, **2021**, 8, 798364	5.4	1

14	Modifying chronic kidney disease progression with the mineralocorticoid receptor antagonist finerenone in patients with type 2 diabetes.. *Diabetes, Obesity and Metabolism*, **2022**,	6.7	0
13	A case of a pregnant woman with primary aldosteronism and superimposed preeclampsia treated with esaxerenone. *Journal of the Endocrine Society*,	0.4	0
12	Biglycan Is a Novel Mineralocorticoid Receptor Target Involved in Aldosterone/Salt-Induced Glomerular Injury. *International Journal of Molecular Sciences*, **2022**, 23, 6680	6.3	
11	Cardiovascular and Renal Outcomes with Finerenone, a Selective Mineralocorticoid Receptor Antagonist. *Cardiology and Therapy*,	2.8	0
10	The non-steroidal mineralocorticoid receptor antagonist finerenone is a novel therapeutic option for patients with Type 2 diabetes and chronic kidney disease. *Clinical Science*, **2022**, 136, 1005-1017	6.5	0
9	The Diabetic Cardiorenal Nexus. *International Journal of Molecular Sciences*, **2022**, 23, 7351	6.3	1
8	Nonsteroidal Mineralocorticoid Receptor Antagonism by Finerenone Translational Aspects and Clinical Perspectives across Multiple Organ Systems. **2022**, 23, 9243		1
7	Cellular Senescence in Metabolic-Associated Kidney Disease: An Update. **2022**, 11, 3443		0
6	Screening for unilateral aldosteronism should be combined with the maximum systolic blood pressure, history of stroke and typical nodules. **2022**, 101, e31313		0
5	Hypertension in chronic kidney disease: What lies behind the scene. 13,		2
4	Hormone-linked redox status and its modulation by antioxidants. **2023**,		0
3	The Role of Macula Densa Nitric Oxide Synthase 1 Beta Splice Variant in Modulating Tubuloglomerular Feedback. 4215-4229		0
2	The Effect of Aldosterone on Cardiorenal and Metabolic Systems. **2023**, 24, 5370		0
1	Pathophysiological Impact of the MEK5/ERK5 Pathway in Oxidative Stress. **2023**, 12, 1154		0